Biogen adds key manufacturing plant to its potentially quixotic aducanumab launch plan
Biogen’s do-or-die review date for Alzheimer’s hopeful aducanumab is fast approaching, and the drugmaker has made it clear it will prep for a large commercial rollout even with the drug’s chances mixed at best. Now, Biogen will add another manufacturing plant to the supply chain, just in time for a potential approval.
This week, Swiss regulators OK’d Biogen’s Solothurn, Switzerland plant to help produce large-scale batches of aducanumab should it earn FDA approval on June 7, the company said. The facility combines new technology for fed-batch cell culture and protein purification and will complement Biogen’s existing plant in Research Triangle Park, NC. The site could also be used to manufacture another Alzheimer’s hopeful, lecanemab, among other drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.